MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a common nutrient shield young cancer patients from Chemo's toxic side effects?
Disease control Recruiting nowThis study aims to see if adding a nutrient called levocarnitine to standard chemotherapy can prevent severe liver damage in teenagers and young adults (ages 15-39) being treated for leukemia or lymphoma. A key chemotherapy drug, asparaginase, often causes liver toxicity, which c…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 03, 2026 21:10 UTC
-
New immune cell therapy aims to stop Leukemia's return in kids
Disease control Recruiting nowThis study is testing a new treatment for children and young adults with acute leukemia that has not responded well to standard chemotherapy. The treatment combines a stem cell transplant with infusions of specially boosted immune cells (NK cells) from a donor. The main goals are…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug duo tested in fight against Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing whether combining two new drugs, revumenib and mezigdomide, is a safe and effective treatment for people with specific types of acute leukemia that have come back or not responded to prior therapy. It will involve about 52 participants aged 12 and older who …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Scientists test 'Smart Bomb' drug combo against aggressive leukemia
Disease control Recruiting nowThis early-stage study is testing a new combination treatment for adults newly diagnosed with high-risk forms of acute myeloid leukemia (AML) and related blood cancers. The trial combines a standard chemotherapy regimen (FLAG-Ida) with an experimental targeted drug called pivekim…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New transplant approach aims to tame deadly blood cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a modified stem cell transplant called Orca-T, combined with two anti-rejection drugs, for adults with advanced blood cancers like leukemia. The goal is to see if this approach is safe when using a donor who is a partial genetic mat…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New transplant strategy offers hope for tough blood cancers
Disease control Recruiting nowThis study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for tough blood cancers: stronger treatment before transplant
Disease control Recruiting nowThis study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test 'Engineered' transplant to fight blood cancers with fewer side effects
Disease control Recruiting nowThis early-stage trial is testing the safety of a modified donor stem cell transplant, called Orca-Q, for people with certain blood cancers like leukemia. The goal is to see if this engineered transplant can help patients recover their blood counts while reducing serious complica…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough blood cancers: scientists test supercharged cord blood transplants
Disease control Recruiting nowThis study is testing a refined procedure for umbilical cord blood transplants in adults and children with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach improves survival and reduces complications compared to standard transplant…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New cell therapy aims to tame transplant dangers for frail blood cancer patients
Disease control Recruiting nowThis study is testing a new cell therapy called Orca-T for adults with acute myeloid leukemia or myelodysplastic syndrome who need a stem cell transplant but are too frail for the strongest chemotherapy. The therapy uses specially prepared donor cells to help rebuild the patient'…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for kids with tough leukemia: major trial matches patients to Cutting-Edge treatments
Disease control Recruiting nowThis study aims to find better treatments for children and young adults whose leukemia has returned or is hard to treat. It screens patients' blood and bone marrow to understand their specific cancer and match them to new, targeted therapy trials. The goal is to control the disea…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New transplant technique aims to stop Body's attack on itself in kids with cancer
Disease control Recruiting nowThis study is testing whether removing a specific type of immune cell (called naive T cells) from a donor's stem cells before transplant can prevent chronic graft-versus-host disease in children and young adults with blood cancers. Chronic graft-versus-host disease is a serious c…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New 'Smart Bomb' radiation therapy tested for Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New 'Off-the-Shelf' gene therapy aims to outsmart tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat leukemia: first patients test novel drug
Disease control Recruiting nowThis is the first time a new drug called ziftomenib is being tested in people. The study aims to find a safe and effective dose for adults with advanced acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has returned or not responded to other treatments. It w…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets Tough-to-Treat blood cancers in major trial
Disease control Recruiting nowThis study is testing a new oral medication called revumenib for people with acute leukemias that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will test how well the drug works…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough leukemias: testing a powerful drug cocktail
Disease control Recruiting nowThis study is testing a new combination of cancer drugs for adults with aggressive forms of acute myeloid leukemia (AML) and related blood cancers that are newly diagnosed as high-risk or have come back after previous treatment. The goal is to find the safest and most effective d…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Major trial aims to boost survival for toughest childhood cancers
Disease control Recruiting nowThis large study is testing if adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves long-term survival for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It will also track outcomes for pati…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test new pill cocktail in fight against tough leukemia
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new combination of oral pills (venetoclax and dasatinib) for adults with a specific, aggressive type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) or mixed phenotype acute…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for babies battling rare, aggressive leukemia
Disease control Recruiting nowThis international study is testing a drug called blinatumomab for infants under one year old who have a specific, hard-to-treat type of leukemia. The goal is to see if adding this drug to standard chemotherapy can better control the cancer, prevent it from coming back, and impro…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New oral drug tested for aggressive leukemia that has returned
Disease control Recruiting nowThis early-stage trial is testing the safety and proper dosing of an experimental oral medication called MRX-2843. It is for adolescents and adults whose acute leukemia has come back or has not responded to previous treatments. The main goal is to find the highest dose that can b…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
First-in-Kids trial aims to tame transplant risks for young cancer patients
Disease control Recruiting nowThis study is testing a new type of stem cell transplant for children and young adults with serious blood cancers like leukemia. The transplant uses donor cells that have been specially prepared in a lab. Researchers want to see if this new method is safe and can help patients re…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for kids with tough blood cancers: trial tests adding powerful drugs
Disease control Recruiting nowThis study is testing whether adding one of two targeted drugs, dasatinib or venetoclax, to standard chemotherapy can help children and young adults with newly diagnosed T-cell leukemia or lymphoma. The goal is to see if these additions lead to better early results and improve su…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC
-
Engineered immune cells target Leukemia's return
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
Doctors launch study to find best leukemia treatment for each child
Knowledge-focused Recruiting nowThis study aims to collect the detailed information doctors need to choose the most appropriate treatment plan for children newly diagnosed with certain types of acute leukemia. Children aged 1-18 will receive 7 days of initial chemotherapy while their cancer cells are tested. Th…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE4 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Mar 06, 2026 15:38 UTC